Prussian blue (PB) is an efficient drug for enhancing cesium elimination from the body. Literature data on the efficacy of PB treatment in dosages that vary from 1–10 g d−1 was reviewed. Cesium biokinetics was simulated using a detailed systemic biokinetic model. The same model was used to simulate the maximum action of PB by interrupting the enterohepatic circulation. Model results reproduced reasonably well the literature data on the efficacy of PB administered to humans after incidental cesium intakes, as well as results from animal experiments. Maximum efficiency of the reduction of the long-term half-time is obtained with the administration of 3 g d−1 PB to the adult. Maximum efficiency of reducing the Cs body burdens is obtained when PB is administered on the first day after the intake, due to the increase of the short-term elimination of cesium. The model predicts that reduction of the long-term half-life is not affected by the time after intake that PB is administered, as long as it is given within the interval from 1 h to 1 y after the intake.